Literature DB >> 2329677

Transplantation.

T E Starzl, J J Fung.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2329677      PMCID： PMC2962591     

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  17 in total

1.  Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.

Authors: 
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Early trials with FK 506 as primary treatment in liver transplantation.

Authors:  S Todo; J J Fung; A J Demetris; A Jain; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  Augmentation of rat liver regeneration by FK 506 compared with cyclosporin.

Authors:  A Francavilla; M Barone; S Todo; Q Zeng; K A Porter; T E Starzl
Journal:  Lancet       Date:  1989-11-25       Impact factor: 79.321

5.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

6.  Isolation and amino acid sequence of cyclophilin.

Authors:  M W Harding; R E Handschumacher; D W Speicher
Journal:  J Biol Chem       Date:  1986-06-25       Impact factor: 5.157

7.  The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein.

Authors:  B H Shieh; M A Stamnes; S Seavello; G L Harris; C S Zuker
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

8.  Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft--a pilot study.

Authors:  D Cantarovich; B Le Mauff; M Hourmant; M Giral; M Denis; M Hirn; Y Jacques; J P Soulillou
Journal:  Transplantation       Date:  1989-03       Impact factor: 4.939

9.  Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin.

Authors:  N Takahashi; T Hayano; M Suzuki
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

10.  The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase.

Authors:  G Fischer; H Bang
Journal:  Biochim Biophys Acta       Date:  1985-03-22
View more
  14 in total

1.  Inhibition of liver, kidney, and intestine regeneration by rapamycin.

Authors:  A Francavilla; T E Starzl; C Scotti; G Carrieri; A Azzarone; Q H Zeng; K A Porter; S L Schreiber
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

2.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

3.  Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases.

Authors:  N L Nikolaidis; K Abu-Elmagd; A W Thomson; H R Rilo; W D Irish; D H Van Thiel; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

Authors:  J J Fung; S Todo; A Tzakis; A Demetris; A Jain; K Abu-Elmaged; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  Use of FK 506 in pediatric patients.

Authors:  A G Tzakis; J J Fung; S Todo; J Reyes; M Green; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

6.  Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

Authors:  L Mieles; R D Gordon; D Mintz; R M Toussaint; O Imventarza; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

7.  Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin.

Authors:  T E Starzl; S L Schreiber; M W Albers; K A Porter; C S Foglieni; A Francavilla
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

8.  Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.

Authors:  S Takaya; O Bronsther; K Abu-Elmagd; H Ramos; J J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1993-06       Impact factor: 1.066

9.  Adverse effects of FK 506 overdosage after liver transplantation.

Authors:  M Alessiani; U Cillo; J J Fung; W Irish; K Abu-Elmagd; A Jain; S Takaya; D Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 10.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.